Willow vs Wellorithm: Oral GLP-1 with Tracking vs 50-State Compounds
Willow vs Wellorithm pits Willow’s telehealth-first oral GLP-1 program with progress tracking and follow-up against Wellorithm’s 50-state compounded semaglutide and tirzepatide offerings. Quick verdict: choose Willow if you want a structured digital follow-up program focused on behavior and tracking; choose Wellorithm if you need broad state coverage and access to both compounded semaglutide and tirzepatide.
Explore Willow’s tracking-first program
Side-by-side summary of Willow vs Wellorithm
Both platforms deliver GLP-1 treatment via telehealth when a licensed clinician determines it is medically appropriate. Key differences arise in treatment format, drug options, clinician coverage, pricing transparency, and program framing.
What each provider emphasizes
Willow emphasizes a structured weight management journey that pairs oral GLP-1 with progress tracking tools and follow-up consultations. Willow frames its program as behavioral scaffolding to convert medication effects into sustainable outcomes and describes a licensed telehealth team supporting that workflow. Treatment is available only when a licensed clinician determines it is medically appropriate. Compounded medications, when offered by Willow, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Wellorithm emphasizes access: it offers compounded semaglutide and compounded tirzepatide, licensed clinicians in all 50 states, and fully virtual consultations with medication shipped to the home. Wellorithm notes treatment is available only when a licensed clinician determines it is medically appropriate and that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Check Wellorithm’s 2-minute eligibility quiz
Top differences: program model, medication options, clinician reach
Program model: Willow is built as a structured weight management journey with progress tracking tools and follow-up consultations. Wellorithm is positioned as an access-focused telehealth platform that delivers compounded GLP-1s after a virtual intake and ships medication to the home.
Medication options: Willow highlights oral GLP-1 within its tracked program. Wellorithm offers both compounded semaglutide and compounded tirzepatide and lists multiple formulation options on its landing content.
Clinician coverage: Willow describes a licensed telehealth team, but captured evidence does not show national coverage details. Wellorithm explicitly states licensed clinicians in all 50 states, which the source frames as an advantage for patients in states with limited telehealth options.
Pricing and transparency
Willow’s captured starting price shows 299. Wellorithm’s landing content advertises starting options such as only $147 and lists various starting figures for different compounds and formats, but the source also notes Wellorithm does not publish full pricing on its website and you receive a personalized quote after the intake quiz. Wellorithm’s source repeatedly states promotional starting points and offers vary by product. Where pricing is not supplied in detail by either provider, this article reports only the captured starting figures and disclaimers from the source.
See Willow program details and pricing
Safety, regulatory, and clinical process
Both sources stress that treatment is available only when a licensed clinician determines it is medically appropriate. Both sources also include the regulatory note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Willow specifically notes that compounded medications, when offered, are not FDA-approved. Wellorithm’s content repeats that compounded medications are not FDA-approved and explains medications are compounded at licensed pharmacies and use the same active ingredients as branded versions, per the captured evidence.
Quick comparison table
| Criteria | Willow | Wellorithm |
|---|---|---|
| Program framing | Structured weight management with progress tracking and follow-up consultations | Access-focused telehealth with intake quiz and virtual prescribing |
| Medication options | Oral GLP-1 emphasized; compounded medications noted when offered | Compounded semaglutide and compounded tirzepatide available |
| Clinician coverage | Licensed telehealth team (coverage details not captured) | Licensed clinicians in all 50 states |
| Starting price (captured) | 299 | Only $147 and other starting figures shown; full pricing requires intake quote |
| Follow-up and tracking | Progress tracking tools and follow-up consultations emphasized | Ongoing virtual check-ins to support titration |
Practical differences that matter to patients
If you prioritize a program that explicitly couples medication with structured behavior change, Willow’s emphasis on progress tracking and follow-up consultations is the primary differentiator. If you need guaranteed clinician access in any U.S. state or want both semaglutide and tirzepatide compounds available, Wellorithm’s 50-state clinician network and broader compound options are the main advantages. Both require clinician approval and both note compounded medications are not FDA-approved.
Start Wellorithm’s eligibility quiz
Conclusion: Willow vs Wellorithm
Willow vs Wellorithm delivers two different telehealth approaches from the captured evidence. Willow is presented as a structured, tracking-first oral GLP-1 program with follow-up support and a captured starting price of 299. Wellorithm is presented as a national telehealth platform offering compounded semaglutide and tirzepatide with licensed clinicians in all 50 states, promotional starting points such as $147, and pricing that may require a personalized quote. Both platforms state treatment is available only when a licensed clinician determines it is medically appropriate and that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Choose Willow if you want a program framed around progress tracking and regular follow-up from a licensed telehealth team.
Choose Wellorithm if you need clinician access in any U.S. state or access to both compounded semaglutide and compounded tirzepatide as part of a fully virtual program.